Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06006117
Title Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors The Lymphoma Academic Research Organisation
Age Groups: adult | senior
Covered Countries FRA

No variant requirements are available.